Pediatrix Medical Group, Inc. (MD) Income Statement Analysis

See more : Noble Engineering Group Holdings Limited (8445.HK) Income Statement Analysis – Financial Results

Complete financial analysis of Pediatrix Medical Group, Inc. (MD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pediatrix Medical Group, Inc., a leading company in the Medical – Care Facilities industry within the Healthcare sector.

You may be interested

Pediatrix Medical Group, Inc. (MD)

Industry: Medical - Care Facilities

Sector: Healthcare

Website: https://www.mednax.com

About Pediatrix Medical Group, Inc.

Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. As of February 17, 2022, it operated a network of approximately 2,700 physicians. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994
Revenue	1.99B	1.97B	1.91B	1.73B	3.51B	3.65B	3.46B	3.18B	2.78B	2.44B	2.15B	1.82B	1.59B	1.40B	1.29B	1.07B	917.64M	818.55M	693.70M	619.63M	551.20M	465.48M	354.60M	243.08M	227.00M	185.40M	128.90M	80.80M	43.90M	32.80M
Cost of Revenue	1.57B	1.50B	1.40B	1.28B	2.62B	2.66B	2.46B	2.15B	1.85B	1.63B	1.44B	1.20B	1.04B	912.43M	835.73M	688.21M	567.38M	501.55M	27.68M	24.25M	18.59M	15.79M	0.00	26.68M	21.10M	14.10M	9.80M	6.30M	3.50M	2.80M
Gross Profit	421.57M	467.03M	513.24M	449.32M	892.00M	989.51M	1.00B	1.03B	928.01M	806.52M	710.31M	613.88M	551.04M	489.13M	452.54M	380.07M	350.26M	317.00M	666.02M	595.38M	532.61M	449.69M	354.60M	216.40M	205.90M	171.30M	119.10M	74.50M	40.40M	30.00M
Gross Profit Ratio	21.13%	23.68%	26.85%	25.91%	25.39%	27.13%	28.92%	32.47%	33.38%	33.07%	32.98%	33.79%	34.69%	34.90%	35.13%	35.58%	38.17%	38.73%	96.01%	96.09%	96.63%	96.61%	100.00%	89.03%	90.70%	92.39%	92.40%	92.20%	92.03%	91.46%
Research & Development	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	227.54M	231.40M	263.36M	248.95M	404.64M	432.38M	417.11M	372.57M	305.92M	247.53M	218.21M	193.54M	170.36M	154.27M	124.97M	124.97M	119.77M	109.06M	115.30M	79.45M	76.54M	0.00	274.72M	177.72M	148.90M	113.70M	81.50M	52.70M	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	22.20M	0.00	0.00	0.00	393.14M	350.35M	310.78M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	227.54M	231.40M	263.36M	248.95M	404.64M	432.38M	417.11M	372.57M	305.92M	247.53M	218.21M	193.54M	170.36M	154.27M	147.16M	124.97M	119.77M	109.06M	508.44M	429.80M	387.32M	331.48M	274.72M	177.72M	148.90M	113.70M	81.50M	52.70M	29.50M	20.70M
Other Expenses	186.70M	35.64M	32.15M	28.44M	78.86M	111.28M	102.88M	89.26M	64.23M	45.99M	39.97M	30.82M	25.29M	21.95M	16.45M	13.07M	9.59M	9.47M	9.92M	9.35M	8.41M	6.14M	21.44M	13.81M	12.10M	8.70M	4.50M	1.80M	400.00K	200.00K
Operating Expenses	414.24M	267.03M	295.50M	277.39M	483.50M	543.66M	519.98M	461.84M	370.14M	293.52M	258.18M	224.36M	215.65M	176.22M	163.61M	826.25M	129.36M	118.53M	518.36M	439.15M	395.72M	337.62M	296.16M	191.53M	161.00M	122.40M	86.00M	54.50M	29.90M	20.90M
Cost & Expenses	1.99B	1.77B	1.69B	1.56B	3.11B	3.20B	2.98B	2.61B	2.22B	1.93B	1.70B	1.43B	1.25B	1.09B	999.34M	826.25M	696.74M	620.08M	546.03M	463.41M	414.31M	353.41M	296.16M	218.20M	182.10M	136.50M	95.80M	60.80M	33.40M	23.70M
Interest Income	0.00	3.67M	13.65M	17.91M	3.69M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	42.08M	39.70M	68.72M	110.48M	119.38M	88.77M	74.56M	63.09M	23.11M	8.89M	5.42M	3.25M	3.64M	3.19M	2.91M	3.59M	749.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	36.17M	35.64M	32.15M	28.44M	25.93M	83.83M	102.88M	89.26M	64.23M	45.99M	39.97M	30.82M	25.29M	21.95M	16.45M	13.07M	10.56M	9.47M	9.92M	9.35M	8.41M	6.14M	21.44M	13.81M	12.10M	8.70M	4.50M	1.80M	400.00K	200.00K
EBITDA	29.89M	235.64M	249.89M	200.37M	258.58M	527.69M	587.86M	660.95M	622.10M	558.99M	492.10M	422.23M	382.18M	336.30M	307.06M	258.22M	224.61M	204.11M	156.40M	164.68M	145.29M	118.21M	79.88M	38.68M	57.00M	57.60M	37.60M	21.80M	10.90M	9.30M
EBITDA Ratio	1.50%	12.04%	13.17%	11.65%	14.09%	15.46%	16.88%	20.86%	22.49%	22.99%	22.85%	23.14%	23.97%	23.89%	23.70%	23.88%	24.48%	24.94%	22.55%	26.58%	26.27%	25.22%	22.53%	15.77%	24.98%	30.74%	27.54%	24.50%	23.01%	27.74%
Operating Income	7.32M	172.69M	202.92M	173.52M	416.27M	445.85M	480.08M	571.69M	557.87M	513.00M	452.13M	389.52M	355.39M	312.91M	288.93M	242.03M	220.90M	198.47M	147.67M	156.22M	136.89M	112.08M	58.44M	24.87M	44.90M	48.90M	33.10M	20.00M	10.50M	9.10M
Operating Income Ratio	0.37%	8.76%	10.62%	10.01%	11.85%	12.22%	13.88%	17.96%	20.07%	21.03%	20.99%	21.44%	22.38%	22.33%	22.43%	22.66%	24.07%	24.25%	21.29%	25.21%	24.83%	24.08%	16.48%	10.23%	19.78%	26.38%	25.68%	24.75%	23.92%	27.74%
Total Other Income/Expenses	-55.68M	-91.32M	-67.69M	-90.98M	-112.97M	120.45M	-69.65M	-57.89M	-18.14M	-4.38M	-3.72M	-1.35M	-2.14M	-1.76M	-1.23M	-611.00K	6.11M	2.80M	3.70M	-402.00K	-890.00K	-338.00K	-2.23M	-3.41M	-2.30M	-400.00K	1.70M	2.00M	700.00K	0.00
Income Before Tax	-48.36M	81.37M	135.23M	7.15M	-1.24B	368.84M	410.42M	513.80M	539.73M	508.62M	448.41M	388.17M	353.25M	311.15M	287.70M	241.42M	227.01M	201.28M	146.58M	155.82M	136.00M	111.74M	56.21M	21.46M	42.60M	48.50M	34.80M	22.00M	11.20M	9.10M
Income Before Tax Ratio	-2.42%	4.13%	7.08%	0.41%	-35.35%	10.11%	11.87%	16.14%	19.41%	20.85%	20.82%	21.37%	22.24%	22.20%	22.33%	22.60%	24.74%	24.59%	21.13%	25.15%	24.67%	24.00%	15.85%	8.83%	18.77%	26.16%	27.00%	27.23%	25.51%	27.74%
Income Tax Expense	12.05M	18.81M	27.24M	16.73M	-91.89M	100.21M	90.05M	189.20M	204.04M	191.41M	167.90M	147.26M	135.25M	108.46M	111.90M	94.74M	86.99M	76.81M	57.54M	57.54M	51.67M	42.96M	25.78M	10.47M	17.60M	19.40M	13.90M	8.90M	4.50M	3.70M
Net Income	-60.41M	66.34M	130.96M	-9.58M	-1.15B	268.63M	320.37M	324.91M	336.32M	317.28M	280.52M	240.91M	218.00M	202.69M	175.80M	169.20M	142.72M	124.47M	89.04M	98.28M	84.33M	68.78M	30.43M	10.99M	25.00M	29.10M	20.90M	13.10M	6.70M	5.40M
Net Income Ratio	-3.03%	3.36%	6.85%	-0.55%	-32.73%	7.37%	9.26%	10.21%	12.10%	13.01%	13.02%	13.26%	13.73%	14.46%	13.65%	15.84%	15.55%	15.21%	12.84%	15.86%	15.30%	14.78%	8.58%	4.52%	11.01%	15.70%	16.21%	16.21%	15.26%	16.46%
EPS	-0.72	0.79	1.54	-0.11	-13.77	2.95	3.42	3.47	3.59	3.30	2.77	2.41	2.23	2.17	1.87	1.85	1.48	1.30	0.47	0.51	0.89	0.67	0.36	0.18	0.40	0.24	0.09	0.11	0.04	0.04
EPS Diluted	-0.73	0.79	1.53	-0.11	-13.77	2.93	3.42	3.47	3.58	3.18	2.77	2.41	2.23	2.13	1.87	1.80	1.43	1.26	0.46	0.48	0.86	0.65	0.34	0.17	0.40	0.23	0.08	0.11	0.04	0.03
Weighted Avg Shares Out	84.02M	83.47M	84.83M	83.40M	83.50M	91.10M	92.43M	92.42M	93.74M	96.03M	100.91M	99.55M	97.87M	93.26M	90.92M	92.83M	96.92M	95.85M	185.94M	190.65M	94.97M	102.49M	84.64M	63.04M	62.05M	60.99M	121.13M	116.28M	52.20M	52.04M
Weighted Avg Shares Out (Dil)	82.20M	84.12M	85.83M	83.40M	83.50M	91.61M	93.72M	93.72M	93.96M	99.89M	101.21M	100.04M	97.87M	95.14M	92.94M	94.32M	99.81M	98.77M	192.16M	198.94M	98.31M	106.52M	89.91M	64.21M	63.44M	63.95M	121.13M	116.44M	52.20M	52.04M

Pediatrix (MD) Up 8% Since Q2 Earnings Release, Revenues Up Y/Y

August 16, 2022zacks.com

Pediatrix's (MD) second-quarter results reflect growth in patient volumes. Adjusted EBITDA is expected within $260-$270 million for 2022.

Pediatrix Medical Group, Inc. (MD) CEO Mark Ordan on Q2 2022 Results - Earnings Call Transcript

August 7, 2022seekingalpha.com

Pediatrix Medical Group, Inc. (NYSE:MD ) Q2 2022 Earnings Conference Call August 4, 2022 9:00 AM ET Corporate Participants Charles Lynch - Investor Relations Mark Ordan - Chief Executive Officer Marc Richards - Chief Financial Officer Conference Call Participants Tao...

Mednax (MD) Q2 Earnings Match Estimates

August 4, 2022zacks.com

Mednax (MD) delivered earnings and revenue surprises of 0% and 1.34%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Pediatrix Medical Group Reports Second Quarter Results

August 4, 2022businesswire.com

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Pediatrix Medical Group, Inc. (NYSE: MD), the nation’s leading provider of highly specialized health care for women, children and babies, today reported earnings from continuing operations of $0.36 per share for the three months ended June 30,...